Atherosclerosis
Volume 204, Issue 2 , Pages 471-475 , June 2009

Raloxifene reduces circulating levels of interleukin-7 and monocyte chemoattractant protein-1 in postmenopausal women

  • Toshiyuki Yasui

      Affiliations

    • Department of Obstetrics and Gynecology, Course of Human Development, Human Development and Health Science, Institute of Health Biosciences, The University of Tokushima Graduate School, 3-18-15 Kuramoto, Tokushima 770-8503, Japan
    • Corresponding Author InformationCorresponding author. Fax: +81 88 631 2630.
    • ,
  • Hirokazu Uemura

      Affiliations

    • Department of Preventive Medicine, Course of Human Development, Human Development and Health Science, Institute of Health Biosciences, The University of Tokushima Graduate School, Japan
    • ,
  • Sari Hyodo

      Affiliations

    • Course of Medicine, School of Medicine, The University of Tokushima, Japan
    • ,
  • Masayo Yamada

      Affiliations

    • Department of Obstetrics and Gynecology, Course of Human Development, Human Development and Health Science, Institute of Health Biosciences, The University of Tokushima Graduate School, 3-18-15 Kuramoto, Tokushima 770-8503, Japan
    • ,
  • Satoshi Yamamoto

      Affiliations

    • Department of Obstetrics and Gynecology, Course of Human Development, Human Development and Health Science, Institute of Health Biosciences, The University of Tokushima Graduate School, 3-18-15 Kuramoto, Tokushima 770-8503, Japan
    • ,
  • Masahiko Maegawa

      Affiliations

    • Department of Obstetrics and Gynecology, Course of Human Development, Human Development and Health Science, Institute of Health Biosciences, The University of Tokushima Graduate School, 3-18-15 Kuramoto, Tokushima 770-8503, Japan
    • ,
  • Naoko Tsuchiya

      Affiliations

    • Pharmacology Research Department, Tsumura Central Research Institute, Japan
    • ,
  • Masamichi Noguchi

      Affiliations

    • Pharmacology Research Department, Tsumura Central Research Institute, Japan
    • ,
  • Mitsutoshi Yuzurihara

      Affiliations

    • Pharmacology Research Department, Tsumura Central Research Institute, Japan
    • ,
  • Yoshio Kase

      Affiliations

    • Pharmacology Research Department, Tsumura Central Research Institute, Japan
    • ,
  • Minoru Irahara

      Affiliations

    • Department of Obstetrics and Gynecology, Course of Human Development, Human Development and Health Science, Institute of Health Biosciences, The University of Tokushima Graduate School, 3-18-15 Kuramoto, Tokushima 770-8503, Japan

Received 7 May 2008 ,Revised 27 August 2008 ,Accepted 6 September 2008.

References 

  1. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab. 2001;280:E745–E751
  2. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006;86:515–581
  3. Lagathu C, Yvan-Charvet L, Bastard JP, et al. Long-term treatment with interleukin-1 beta induces insulin resistance in murine and human adipocytes. Diabetologia. 2006;49:2162–2173
  4. Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci USA. 2003;100:7265–7270
  5. Kim CS, Park HS, Kawada T, et al. Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. Int J Obes. 2006;30:1347–1355
  6. Reape TJ, Groot PH. Chemokines and atherosclerosis. Atherosclerosis. 1999;147:213–225
  7. Maury E, Ehala-Aleksejev K, Guiot Y, et al. Adipokines oversecreted by omental adipose tissue in human obesity. Am J Physiol Endocrinol Metab. 2007;293:E656–E665
  8. Barrett-Connor E, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women. JAMA. 2002;287:847–857
  9. Takahashi K, Mori-Abe A, Takata K, et al. Raloxifene improves the ovariectomy-induced impairment in endothelium-dependent vasodilation. Menopause. 2007;14:656–661
  10. Colacurci N, Manzella D, Fornaro F, Carbonella M, Paolisso G. Endothelial function and menopause: effects of raloxifene administration. J Clin Endocrinol Metab. 2003;88:2135–2140
  11. Griffiths KA, Sader MA, Skilton MR, Harmer JA, Celermajer DS. Effects of raloxifene on endothelium-dependent dilation, lipoproteins, and markers of vascular function in postmenopausal women with coronary artery disease. J Am Coll Cardiol. 2003;42:698–704
  12. Ceresini G, Marchini L, Rebecchi I, et al. Effects of raloxifene on carotid blood flow resistance and endothelium-dependent vasodilation in postmenopausal women. Atherosclerosis. 2003;167:121–127
  13. Barrett-Connor E, et al. Effects of raloxifne on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355:125–137
  14. Colacurci N, Fornaro F, Cobellis L, et al. Raloxifene slows down the progression of intima-media thickness in postmenopausal women. Menopause. 2007;14:879–884
  15. Blum A, Schenke WH, Hathaway L, et al. Effects of estrogen and the selective estrogen receptor modulator raloxifene on markers of inflammation in postmenopausal women. Am J Cardiol. 2000;86:892–895
  16. Walsh BW, Cox DA, Sashegyi A, et al. Role of tumor necrosis factor-α and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women. Am J Cardiol. 2001;88:825–828
  17. Gianni W, Ricci A, Gazzaniga P, et al. Raloxifene modulates interleukin-6 and tumor necrosis factor-α synthesis in vivo: results from a pilot clinical study. J Clin Endocrinol Metab. 2004;89:6097–6099
  18. Yasui T, Maegawa M, Tomita J, et al. Changes in serum cytokine concentrations during the menopausal transition. Maturitas. 2007;56:396–403
  19. Ligthart GJ, Corberand JX, Fournier C, et al. Admission criteria for immunogerontological studies in man: the SENIEUR protocol. Mech Ageing Dev. 1984;28:47–55
  20. Murase Y, Kobayashi J, Nohara A, et al. Raloxifene promotes adipocyte differentiation of 3T3-L1 cells. Eur J Pharmacol. 2006;538:1–4
  21. Dus D, Krawczenko A, Zalecki P, et al. IL-7 receptor is present on human microvascular endothelial cells. Immunol Lett. 2003;68:163–168
  22. Krishnaswamy G, Kelley J, Yerra L, Smith JK, Chi DS. Human endothelium as a source of multifunctional cytokines: molecular regulation and possible role in human disease. J Interferon Cytokine Res. 1999;19:91–104
  23. Yla-Herttuala S, Lipton BA, Rosenfeld ME, et al. Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci USA. 1991;88:5252–5256
  24. Seli E, Pehlivan T, Selam B, Garcia-Velasco JA, Arici A. Estradiol down-regulates MCP-1 expression in human coronary artery endothelial cells. Fertil Steril. 2002;77:542–547
  25. Takahashi K, Mizuarai S, Araki H, et al. Adiposity elevates plasma MCP-1 levels leading to the increased CD11b-positive monocytes in mice. J Biol Chem. 2003;278:46654–46660
  26. Miyatani Y, Yasui T, Uemura H, et al. Associations of circulating adiponectin with estradiol and monocyte chemotactic protein-1 in postmenopausal women. Menopause. 2008;15:536–541
  27. Han KH, Tangirala RK, Green SR, Quehenberger O. Chemokine receptor CCR2 expression and monocyte chemoattractant protein-1-mediated chemotaxis in human monocytes. A regulatory role for plasma LDL. Arterioscler Thromb Vas Biol. 1998;18:1983–1991
  28. Cushing SD, Berliner JA, Valente AJ, et al. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA. 1990;87:5134–5138
  29. Rezaie-Majd A, Maca T, Bucek RA, et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol. 2002;22:1194–1199
  30. Ozmen B, Kirmaz C, Aydin K, et al. Influence of the selective oestrogen receptor modulator (raloxifne hydrochloride) on IL-6, TNF-α. TGF-β1 and bone turnover markers in the treatment of postmenopausal osteoporosis. Eur Cytokine Netw. 2007;18:148–153
  31. Yasui T, Maegawa M, Tomita J, et al. Association of serum cytokine concentrations with psychological symptoms in midlife women. J Reprod ImmunoI. 2007;75:56–62
  32. Alesci S, Martinez PE, Kelkar S, et al. Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: clinical implications. J Clin Endocrinol Metab. 2005;90:2522–2530
  33. Judd AM, Call GB, Barney M, et al. Possible function of IL-6 and TNF as intraadrenal factors in the regulation of adrenal steroid secretion. Ann N Y Acad Sci. 2000;917:628–637
  34. Bruun JM, Lihn AS, Madan AK, et al. Higher production of IL-8 in visceral vs. subcutaneous adipose tissue. Implication of nonadipose cells in adipose tissue. Am J Physiol Endocrinol Metab. 2004;286:E8–E13
  35. Yasui T, Uemura H, Tomita J, et al. Association of interleukin-8 with hot flashes in premenopausal, perimenopausal, and postmenopausal women and bilateral oophorectomized women. J Clin Endocrinol Metab. 2006;91:4805–4808
  36. Baek KH, Oh KW, Lee WY, et al. Changes in the serum sex steroids. IL-7 and RANKL-OPG system after bone marrow transplantation: influences on bone and mineral metabolism. Bone. 2006;39:1352–1360
  37. Weitzmann MN, Roggia C, Toraldo G, Weitzmann L, Pacifici R. Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency. J Clin Invest. 2002;110:1643–1650
  38. Cheung J, Mak YT, Papaioannuou S, et al. Interleukin-6 (IL-6), IL-1, receptor activator of nuclear κB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effect of 17β-oestradiol and raloxifene. J Endocrinol. 2003;177:423–433

PII: S0021-9150(08)00671-0

doi: 10.1016/j.atherosclerosis.2008.09.014

Atherosclerosis
Volume 204, Issue 2 , Pages 471-475 , June 2009

Article Tools